HC Wainwright Weighs in on Krystal Biotech Q1 Earnings

Krystal Biotech, Inc. (NASDAQ:KRYS) – Analysts at HC Wainwright issued their Q1 2026 earnings estimates for Krystal Biotech in a research note issued on Wednesday, February 18th. HC Wainwright analyst J. Pantginis forecasts that the company will post earnings of $1.30 per share for the quarter. HC Wainwright has a “Buy” rating and a $310.00 price objective on the stock. The consensus estimate for Krystal Biotech’s current full-year earnings is $6.14 per share.

Krystal Biotech (NASDAQ:KRYS) last posted its quarterly earnings results on Tuesday, February 17th. The company reported $1.70 EPS for the quarter, topping the consensus estimate of $1.62 by $0.08. The firm had revenue of $107.11 million for the quarter, compared to the consensus estimate of $105.30 million. Krystal Biotech had a net margin of 52.64% and a return on equity of 18.69%.

KRYS has been the subject of several other research reports. The Goldman Sachs Group increased their price objective on Krystal Biotech from $206.00 to $327.00 and gave the stock a “buy” rating in a report on Friday, January 30th. Chardan Capital upped their target price on Krystal Biotech from $220.00 to $323.00 and gave the company a “buy” rating in a report on Wednesday. Zacks Research lowered Krystal Biotech from a “strong-buy” rating to a “hold” rating in a research note on Thursday, February 5th. TD Cowen reiterated a “buy” rating on shares of Krystal Biotech in a report on Friday, January 9th. Finally, Weiss Ratings raised shares of Krystal Biotech from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday. Nine equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $318.75.

Krystal Biotech Stock Performance

Shares of Krystal Biotech stock opened at $262.67 on Thursday. Krystal Biotech has a 52-week low of $122.80 and a 52-week high of $298.30. The company’s 50 day moving average price is $265.16 and its 200-day moving average price is $208.78. The stock has a market capitalization of $7.68 billion, a price-to-earnings ratio of 38.35 and a beta of 0.49.

Institutional Trading of Krystal Biotech

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Royal Bank of Canada grew its position in Krystal Biotech by 145.2% during the 1st quarter. Royal Bank of Canada now owns 1,628 shares of the company’s stock worth $294,000 after acquiring an additional 964 shares during the last quarter. AQR Capital Management LLC boosted its stake in Krystal Biotech by 29.9% during the 1st quarter. AQR Capital Management LLC now owns 12,131 shares of the company’s stock valued at $2,187,000 after purchasing an additional 2,792 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Krystal Biotech by 4.5% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,893 shares of the company’s stock valued at $2,870,000 after purchasing an additional 688 shares during the last quarter. Empowered Funds LLC purchased a new stake in shares of Krystal Biotech during the 1st quarter valued at $218,000. Finally, CWM LLC raised its stake in shares of Krystal Biotech by 7.2% during the 2nd quarter. CWM LLC now owns 1,583 shares of the company’s stock worth $218,000 after purchasing an additional 107 shares during the period. Institutional investors own 86.29% of the company’s stock.

Insider Buying and Selling

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction dated Thursday, December 4th. The shares were sold at an average price of $220.16, for a total value of $5,504,000.00. Following the transaction, the insider directly owned 1,413,711 shares of the company’s stock, valued at $311,242,613.76. This represents a 1.74% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CAO Kathryn Romano sold 12,500 shares of Krystal Biotech stock in a transaction on Monday, February 9th. The stock was sold at an average price of $272.14, for a total value of $3,401,750.00. Following the sale, the chief accounting officer directly owned 19,318 shares of the company’s stock, valued at $5,257,200.52. This represents a 39.29% decrease in their position. The SEC filing for this sale provides additional information. 13.70% of the stock is owned by company insiders.

Key Krystal Biotech News

Here are the key news stories impacting Krystal Biotech this week:

• Positive Sentiment: Q4 earnings beat consensus and management highlighted Vyjuvek sales growth and pipeline progress — Vyjuvek sales rose (~17% cited by coverage) and the company reported expanding U.S. reimbursements (660+), supporting revenue and margin outlooks. Read More.
• Positive Sentiment: Analysts are lifting targets and maintaining Buy views — Chardan raised its price target to $323 (Buy) and HC Wainwright keeps a Buy with a $310 target and quarterly EPS estimates, signaling continued analyst confidence. Read More. and Read More.
• Positive Sentiment: Pipeline expansion: KB707 and RMAT designation narrative gaining attention — coverage highlights KB707’s role in an oncology story and broader HSV‑1 platform opportunities, which supports longer‑term upside. Read More.
• Neutral Sentiment: Analysts and media are re‑rating the story after new data and target resets — several pieces reassess valuation and strategy after the one‑year rally; useful for investors reassessing risk/reward. Read More.
• Neutral Sentiment: Q4 earnings call transcript and coverage available for deeper read — transcript and analyst notes give more detail on international launches (Italy H2 2026) and margin targets (90–95%). Read More.
• Neutral Sentiment: Short‑interest data shows no meaningful days‑to‑cover signal in the most recent snapshot — not a driver of today’s move. (Report entry: short interest flagged as zero.)
• Negative Sentiment: Stock pulled back despite earnings beat — several outlets note intraday selling and a slip after the print, consistent with profit‑taking following the stock’s strong run and some mixed readthroughs on revenue/margins. Read More.
• Negative Sentiment: Market reaction may reflect short‑term rotation and valuation scrutiny after a one‑year rally to new highs — investors may be locking gains even as fundamental metrics remain supportive. Read More.

About Krystal Biotech

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.